Comparison of Luminex NxTAG Respiratory Pathogen Panel and xTAG Respiratory Viral Panel FAST Version 2 for the Detection of Respiratory Viruses.
10.3343/alm.2017.37.3.267
- Author:
Chun Kiat LEE
1
;
Hong Kai LEE
;
Christopher Wei Siong NG
;
Lily CHIU
;
Julian Wei Tze TANG
;
Tze Ping LOH
;
Evelyn Siew Chuan KOAY
Author Information
1. Department of Laboratory Medicine, National University Hospital, Singapore. evelyn_koay@nuhs.edu.sg
- Publication Type:Brief Communication
- Keywords:
Respiratory tract infections;
Respiratory viral panel;
Evaluation;
Molecular diagnostics
- MeSH:
Coronavirus;
Hand;
Influenza, Human;
Metapneumovirus;
Pathology, Molecular;
Respiratory Tract Infections;
United States Food and Drug Administration
- From:Annals of Laboratory Medicine
2017;37(3):267-271
- CountryRepublic of Korea
- Language:English
-
Abstract:
Owing to advancements in molecular diagnostics, recent years have seen an increasing number of laboratories adopting respiratory viral panels to detect respiratory pathogens. In December 2015, the NxTAG respiratory pathogen panel (NxTAG RPP) was approved by the United States Food and Drug Administration. We compared the clinical performance of this new assay with that of the xTAG respiratory viral panel (xTAG RVP) FAST v2 using 142 clinical samples and 12 external quality assessment samples. Discordant results were resolved by using a laboratory-developed respiratory viral panel. The NxTAG RPP achieved 100% concordant negative results and 86.6% concordant positive results. It detected one coronavirus 229E and eight influenza A/H3N2 viruses that were missed by the xTAG RVP FAST v2. On the other hand, the NxTAG RPP missed one enterovirus/rhinovirus and one metapneumovirus that were detected by FAST v2. Both panels correctly identified all the pathogens in the 12 external quality assessment samples. Overall, the NxTAG RPP demonstrated good diagnostic performance. Of note, it was better able to subtype the influenza A/H3N2 viruses compared with the xTAG RVP FAST v2.
